Scleroderma News

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up!

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care & Research.

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of menopausal hormone therapy, according to data published in Rheumatology.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Frailty among patients with systemic sclerosis significantly increases the risk for mortality by nearly 10-fold, but shows the potential to improve over time, according to data published in Clinical Rheumatology.

After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor T-cell therapies for autoimmune rheumatic diseases.

WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.

WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.